p3

Cambridge Healthtech Institute’s 9th Annual

Bispecific Antibody Therapeutics

Combination Therapy & Engineering Multi-Specificity

January 23-24, 2020

Part of the Antibody Therapeutics pipeline

 

CHI’s Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two targets simultaneously. The conference examines how these molecules are used to fight a wide array of diseases, as well as in combination therapy for enhanced effects in the fight against cancer. Along with increased efficacy, Bispecific Antibody Therapeutics can also optimize expenses by reducing the cost of development and clinical trials. Case studies highlight novel engineering approaches and platform constructs that improve safety, stability, enhanced targeting, and manufacturability.

 

Coverage will include, but is not limited to:

  • Engineering bi- and tri-specific antibodies
  • Engineering multivalency
  • Combination therapy
  • Binding
  • CARs
  • Engaging T cells
  • Bi-specific T-cell engagers (BiTEs)
  • Specificity
  • Assays
  • Target engagement
  • Specific delivery to tissues or cells
  • Case studies
  • Pre-Clinical & clinical data
  • Stability
  • Crossing the Blood-Brain Barrier (BBB)
  • Variable domains
  • Antibody mimetics
  • Antibody-antigen binding kinetics
  • Immunogenicity
  • Effector functions
  • Conquering cancer and other diseases
  • Antitumor activity
  • Tumor-specific antigens (TSAs)
  • Mechanism of Action (MOA)

 

* The program is subject to change without notice, due to unforeseen reason.







2020 Conferences & Training Seminars